Shares are down nearly 45%, but this healthcare innovator may be quietly building the logistics backbone of organ ...

TransMedics Group, Inc. TMDX is well-poised for growth in the coming quarters, courtesy of its strength in Organ Care System ...

TransMedics (Nasdaq:TMDX) today announced the closing of a strategic investment in PAD Aviation, a Germany-based aviation ...

TransMedics Group (NASDAQ: TMDX) was a top-performing stock that more than doubled in value during the months between the end of 2023 and late August. Unfortunately, shares of the healthcare stock ...

Innovations often (but not always) drive life-changing returns for the companies that engineer them and the people who get in on the ground floor. That's why investors should sometimes look toward ...

TransMedics offers a turnkey, end-to-end offering for organ transplants through its Organ Care System (OCS) and its National OCS Program (NOP). Its OCS is a next-gen array of solutions that "replicate ...

From the beginning of 2024 through Aug. 23, shares of TransMedics (NASDAQ: TMDX) stock soared by 123% -- but the good times didn't last. A third-quarter earnings miss sent shares of the ...

TransMedics is rated Buy as the market overreacts to Q1 margin pressure, while the core growth thesis remains intact. Read more on TMDX stock here.

Specializing in organ preservation technology, this medical device innovator reported a notable insider sale amid ongoing ...

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today ...